Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanabenz study in early childhood-onset vanishing white matter disease
NL-OMON55425Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of guanabenz in leukoencephalopathy with vanishing white matter (VWM), sponsored by Vrije University Medical Center. Primary endpoint: Adverse events and serious adverse events. Started May 2021; status: recruiting.
02
Drugs
guanabenz
03
Conditions
leukoencephalopathy with vanishing white matter (VWM)
Beyond the preview
Go deeper on NL-OMON55425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55425.